TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Current prevalence of IAH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure to SH in the past 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial change of plasma phosphate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eczema Area and Severity Index (EASI) score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in score of the 3F Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of anti-SARS-CoV2 seropositive participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total PCA volume consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score at the EVS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proteinuria/creatininuria ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rating of perceived exercise effort (RPE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetics of Mosapride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Donor engraftment after allogeneic bone marrow transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients taking rescue drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Survival to hospital discharge without major disability
Endpoint domain: Mortality/survival
Primary endpoint: Percentage Change in Step Length Asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Double Support Asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Visual Acuity in the Amblyopic Eye at 17 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Favorable Microbiological Response at Completion of IV Study Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With an Elevated Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Laboratory Value That Was Greater Than or Equal to 5 Times the Upper Limit of Normal (ULN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With at Least 1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Numbers of CTC pre- and post- neoadjuvant chemotherapy and after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mutation rate of ctDNA pre- and post- neoadjuvant chemotherapy and after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of cfDNA pre- and post- neoadjuvant chemotherapy and after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of Blood Vessel by Optical Coherence Tomography Angiography (OCTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Participants With Any Thrombotic Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Concentration of Rivaroxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: degree of repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Ponatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Composite Complete Remission (CRc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myopathy frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm isokinetic force at 60 degrees per second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: safety and feasibility of PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dosimetry of trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biodistribution of trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician-Administered PTSD Scale (CAPS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PTSD Checklist-Military (PCL-M) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fMRI brain blood oxygen level-dependent (BOLD) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCC metastasis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Peritonitis resolved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of questionnaire completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain and stress measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active parental involvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Drug concentration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of use of the VistaCare® medical device
Endpoint domain: Adverse events/effects
Primary endpoint: Performance of the VistaCare® device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in LDL-cholesterol/LDL-cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Liver fat measured by MR-S
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Insulin sensitivity (ISI composite) from 3h OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of fractionated CO2 laser treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of adjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombus formation, stability and break down
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LV-LV/RV-LV intra-cardiac conduction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trunk flexion flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum amplitude of hip flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein profile changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolite profile changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Women With Clinical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological disorder incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Smoking Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving Levels (Questionnaire for Smoking Urges -- Brief)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Minnesota Nicotine Withdrawal Scale (MNWS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child's communication regarding stroke symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Variability in Tacrolimus Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased anorectal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Amount of Opiate Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Usability of the device Le Qoos
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-Rated Abilities for Healthy Practices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum 25-hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction or elimination of cocaine craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Drug-Related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Units of packed red blood cells transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline PTSD Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of Glycated hemoglobin (HbA1c) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Onset of hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in the severity of OCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24h-urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of keloid scar recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total dose of morphine consumption in the first 48 hours postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics parameters of HS-10234 and its metabolite tenofovir, Emtricitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SMN1/SMN2 detection in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Subjective Sleep Onset Latency (sSOL)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Abruptio placenta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: In-line fluid pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Became Infected With Wild-Type Cytomegalovirus Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Response or Partial In-field Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Perineum elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance between pubic bone and perineum at 20 kPa load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTc Friderica (QTcF) parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) as Measured by the Number of Participants With Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Volume Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Averaged Maximum Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radical surgical resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in the number of self-reported fruits per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the number of self-reported vegetables per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in number of days a week and minutes per day participants participate in physical activity and sedentary activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Grade 3/4 acute toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in prostate cancer knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Feasibility of integration of BBVR systems
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence rate of exit site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Fractional anisotropy coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acute lung injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Delta change in arterial partial pressure of carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Counts of ≥ Grade 3 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Who Survive Progression-free
Endpoint domain: Mortality/survival
Primary endpoint: Changes in communication skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in interactivity skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Ability to handle challenging behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quicksleeper efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: toxicity and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time alive and free of vasopressors at day 7
Endpoint domain: Mortality/survival
Primary endpoint: Change of left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comfort Rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Leg pain intensity numeric rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global rating of change in the condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in salivary secretory Ig-A concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: development of ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Pain Burden
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Delayed recall on Buschke Selective Reminding Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stroop Interference condition--completion time and errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinician-rated Interview Based Impression of Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With ASAS40 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive Function Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Postoperative Constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: postoperative Ejection Fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occlusion of the below-knee artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Median pain duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Requirement of strong opioid
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC 0-48h) - Chromogenic Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC 0-48h) - aPTT Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HIV DNA quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who achieve virological remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of rhinovirus-induced common colds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Cognitive Ability (IQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dosimetry of 18F MFBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSK Symptom Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: single-dose pharmacokinetics of palifermin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Any, Grade 3 and Related Unsolicited Symptoms (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any and Related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With no Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Intraocular Pressure at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Median Time From First Dose of Omalizumab Treatment to Cessation of New Blisters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Decrease in the Total Body Surface Area Affected By Active Bullous Pemphigoid Skin Disease From Day 0 to Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Median Increase in Prednisone Dosage Measured at Week 4, 8 and 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement measured by Kujala score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vascular Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in Ocular Surface Disease Index (OSDI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With a Vaccine Response for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects for HI Antibody Titers for Each of the 3 Influenza Virus Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects HI Antibody Titers for Each of the 3 Influenza Virus Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Subjects Achieving Corneal Epithelial Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the proportion of CRT responders at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical composite score at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speech motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speech articulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in word-level speech intelligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in long term declarative memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: TxA2 formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Brief Pain Inventory for sustained relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric pain scale (0-10) for immediate relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes